Perspective Therapeutics (CATX) FCF Margin (2010 - 2023)

Perspective Therapeutics has disclosed FCF Margin across 14 years of filings, most recently posting 185.58% for Q4 2023.

• FCF Margin for Q4 2023 came in at 185.58%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 6196.57% (changed N/A YoY), and the FY2023 annual result was 2648.88%, changed N/A from the prior year.
• FCF Margin came in at 185.58% for Q4 2023 at Perspective Therapeutics, up from 506.86% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 185.58% in Q4 2023 to a low of 542.3% in Q1 2023.
• The 5-year median for FCF Margin is 52.88% (2019), against an average of 116.0%.
• Across the five-year window, FCF Margin jumped 13302 bps in 2021 and slumped 49247 bps in 2023, its largest moves.
• Perspective Therapeutics' FCF Margin stood at 62.74% in 2019, then jumped by 45 bps to 34.76% in 2020, then soared by 383 bps to 98.26% in 2021, then tumbled by 210 bps to 107.92% in 2022, then jumped by 272 bps to 185.58% in 2023.
• The last three FCF Margin figures came in at 185.58% (Q4 2023), 506.86% (Q3 2023), and 525.93% (Q2 2023), per Business Quant data.